| Drug Name: | Dacomitinib |
|---|
| Drug Class: | Tyrosine kinase inhibitor |
|---|
| Mechanism of Action: | Inhibits the activity of epidermal growth factor receptor (EGFR) tyrosine kinase |
|---|
| Use: | - Treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations
|
|---|
| Side Effects: | - Diarrhea
- Rash
- Paronychia (inflammation of the nail bed)
- Stomatitis (inflammation of the mouth)
- Decreased appetite
- Fatigue
- Nausea
- Dry skin
|
|---|
| Contraindications: | - Severe hepatic impairment
- Pregnancy
|
|---|
| Specialty: | |
|---|